Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866209 | 0.76 | CYP2D6 (0.34) | MAPTSMN1; SMN2LMNAKDM4EMEN1 | |
| SCHEMBL7866217 | 0.76 | CYP2D6 (0.34) | MAPTSMN1; SMN2LMNAKDM4EMEN1 | |
| SCHEMBL7886462 | 0.75 | HPGD (0.40) | MAPTSMN1; SMN2LMNAKDM4EMEN1 | |
| SCHEMBL7886467 | 0.75 | HPGD (0.40) | MAPTSMN1; SMN2LMNAKDM4EMEN1 | |
| SCHEMBL7069264 | 0.72 | ALDH1A1 (0.33) | MAPTLMNAKDM4EMEN1HTT | |
| SCHEMBL7069267 | 0.72 | ALDH1A1 (0.33) | MAPTLMNAKDM4EMEN1HTT | |
| SCHEMBL2035577 | 0.70 | MAPT (0.41) | NPC1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL1941287 | 0.69 | ALDH1A1 (0.40) | MAPTLMNAKDM4EMEN1HTT | |
| SCHEMBL28540454 | 0.69 | KMT2A (0.37) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL9435237 | 0.68 | MAPT (0.32) | MAPTLMNAKDM4EMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9437828-B2 | Electroluminescent device using azomethine-lithium-complex as electron injection layer | MERCK PATENT GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20150065725-A1 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER | MERCK PATENT GMBH (DE) | 2015-03-05 | — | — | US | disclosed |
| US-8883325-B2 | Electroluminescent device using azomethine-lithium-complex as electron injection layer | MERCK PATENT GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20120205638-A1 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER | MERCK PATENT GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20100327264-A1 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER | MERCK PATNET GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| EP-2095690-B1 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER | MERCK PATENT GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120205638-A1 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER | ACSL3, APOL1, INTS9 | NPC1 1103/4885MAPT 3539/4885SMN1; SMN2 4597/4885 |
| US-20100327264-A1 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER | ACSL3, APOL1, INTS9 | NPC1 1206/4885MAPT 3581/4885SMN1; SMN2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.